We were delighted to talk to Milind Javle (University of Texas MD Anderson Cancer Center, Houston, TX, US) about the use of infigratinib for the treatment of patients with previously treated advanced cholangiocarcinoma (Clinical Trial Identifier: NCT02150967).
The abstract ‘Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement’ (ABSTRACT NUMBER: 265) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
Questions
- What is the mechanism of action of infigratinib? (0:12)
- Could you please give us an overview of the phase II BGJ398 study of infigratinib and its findings? (0:33)
- What will be the next steps in the clinical development of infigratinib? (2:13)
- What are the treatment options for cholangiocarcinoma (CCA) after progression on first-line gemcitabine-based therapy? (3:17)
- Could you give us a brief overview of the clinical development of infigratinib in the treatment of CCA and its likely impact on treatment paradigms in the future? (3:50)
Disclosures: Milind Javle discloses funding/ research support from Incyte, QED, Basilea, Taiho, Astra Zeneca, Merck, EMD Serono, Novartis, Eli Lilly, Meclun and GSK.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
